Novartis tries to make UK hospitals use $1000 drug

<p>LONDON (AP) — Drug builder <span>Novartis</span> is holding authorised movement in Britain to make state-run hospitals use an eye drug that costs about 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).</p>
<p>In a statement, Novartis pronounced it was job for a <span>judicial review</span> “as a final resort” since it believed studious reserve was being potentially compromised.</p>
<p>According to a U.K.’s health watchdog, Novartis’ <span>Lucentis</span> is a usually drug endorsed to provide a eye problem <span>macular degeneration</span> in a country’s state-run <span>National Health Service</span> hospitals.</p>
<p>However, several NHS hospitals have been prescribing a most cheaper Avastin, a cancer drug finished by <span>Genentech Inc.</span>, a auxiliary of Roche, for a same problem even yet it has not been strictly approved.</p>...